Abstract: A method of preparing PAN-based carbon fibers relates to the technical field of materials. The method includes: S1. acrylonitrile, a second monomer and an unsaturated UV-sensitive cross-linking agent are mixed, an initiator is then added and a reaction is performed to obtain a meltable PAN-based copolymer; S2. the meltable PAN-based copolymer and a flow modifier are mixed to obtain a mixture, the mixture is extruded and pelletized, and then melt spinning is performed to obtain nascent fibers, the nascent fibers are stretched and annealed to obtain a PAN-based carbon fiber precursor; S3. ultraviolet irradiation is performed on the PAN-based carbon fiber precursor; S4. the PAN-based carbon fiber precursor after ultraviolet irradiation is pre-oxidized and carbonized to obtain PAN-based carbon fibers.

Abstract: A system including a transmission terminal, used for transmitting a target data packet obtained by encrypting and encapsulating a data flow; a network controller, deployed in a first Internet network and storing routing information from the transmission terminal to a receiving terminal; and a backbone transmission network device, deployed in a backbone transmission network and used for obtaining the routing information and the target data packet forwarded by the first Internet network and forwarding the target data packet to the receiving terminal based on the routing information. The present disclosure solves the technical problem of low efficiency and high cost of data transmission in the conventional techniques.

Abstract: The present disclosure provides a technical solution related to intelligent knowledge learning and question-answering. The technical solution involves extracting knowledge from corpus and providing a user with a question-answering service based on the extracted knowledge.

Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.

Abstract: Disclosed is a method for synthesizing N-(phenylsulfonyl)benzamide compound and intermediate thereof. The method comprises a method for synthesizing a compound 1, comprising conducting a Buchwald-Hartwig coupling reaction as shown below with compound A and compound B in a solvent and in the presence of a base and a palladium catalyst to obtain the compound 1; wherein R is C1-C8 alkyl. The present disclosure synthesizes three intermediate compounds required by the target compound and their preparation methods for the first time. Using the method disclosed in the present disclosure to synthesize the target compound 3 has the advantages of high yield, good purity, easy-to-obtain reaction raw materials, suitable for industrial production.

Abstract: A reinforced punch-free arcuate shower curtain rod includes a base, a sleeve, a short tube, an inner tube, an outer tube, and a pressing member. A double-sided adhesive is disposed on a bottom surface of the pressing member. A positioning block is disposed on the pressing member. The base can be maintained in contact with a wall surface by means of the friction force between the PVC gasket and the wall surface and the adhesive force of the double-sided adhesive. In addition, the positioning block of the pressing member is inserted through the base to be pressed against and in contact with a cambered surface of a front end of the sleeve.

Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are KRAS inhibitors and are thus useful to treat cancer and other diseases.

Abstract: The disclosure discloses a reinforced punch-free arcuate shower curtain rod. The reinforced punch-free arcuate shower curtain rod includes a base, a sleeve, a short tube, an inner tube, an outer tube, and a pressing member. A double-sided adhesive is disposed on a bottom surface of the pressing member. A positioning block is disposed on the pressing member. During use, the pressing member is accurately pasted on a position of a desired height by using the double-sided adhesive, and the base is positioned and assembled on the positioning block together with a PVC gasket on the bottom surface. Since mounting positions of two ends of the base have been determined by using the pressing member, the mounting positions are accurate, and the mounting process is simple and labor-saving.

Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are KRAS inhibitors and are thus useful to treat cancer and other diseases.

Abstract: A system including a transmission terminal, used for transmitting a target data packet obtained by encrypting and encapsulating a data flow; a network controller, deployed in a first Internet network and storing routing information from the transmission terminal to a receiving terminal; and a backbone transmission network device, deployed in a backbone transmission network and used for obtaining the routing information and the target data packet forwarded by the first Internet network and forwarding the target data packet to the receiving terminal based on the routing information. The present disclosure solves the technical problem of low efficiency and high cost of data transmission in the conventional techniques.

Abstract: A seawater desalination system includes an evaporation tank, a heat absorption device, a first pipeline, a second pipeline, a condenser, a third pipeline, a water tank and a solar cell panel. A first closed cavity for containing seawater is provided in the evaporation tank. A first and a second through hole are provided in an inner side wall of the first closed cavity. The heat absorption device is provided in the evaporation tank, and a light inlet of the heat absorption device is opposite to the light absorption surface. A first end of the first pipeline is connected to a liquid supply device of seawater, and a second end thereof is connected to the first through hole. A first end of the second pipeline is connected to the second through hole, a second end thereof is connected to the condenser. The condenser is connected to the water tank.

Abstract: The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, R8, E, Z, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification.

Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b E, and = are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

Abstract: The present disclosure provides compounds represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.